Cargando…
Collaborative Use Repurposing Engine (CURE): FDA-NCATS/NIH Effort to Capture the Global Clinical Experience of Drug Repurposing to Facilitate Development of New Treatments for Neglected and Emerging Infectious Diseases
BACKGROUND: Repurposing approved products has proven a critical strategy to serve unmet medical needs. Historically, 40% of drugs approved for treatment of tropical diseases were repurposed, including albendazole for echinococcosis and neurocysticercosis, and azithromycin for trachoma. Advantages of...
Autores principales: | Stone, Heather, Sacks, Leonard, Tiernan, Rosemary, Duggal, Mili, Sheils, Timothy, Southall, Noel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631680/ http://dx.doi.org/10.1093/ofid/ofx162.030 |
Ejemplares similares
-
546. Capturing Clinician’s Experiences Repurposing Drugs to Inform Future Studies During COVID-19
por: Duggal, Mili, et al.
Publicado: (2020) -
Exploring NCATS In-House Biomedical Data for Evidence-based Drug Repurposing
por: Liu, Fang, et al.
Publicado: (2023) -
1380. Safety of Repurposed Drugs for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: An Analysis of Adverse Events Reported in the Literature
por: Stone, Heather, et al.
Publicado: (2019) -
Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016) -
High Throughput and Computational Repurposing for Neglected Diseases
por: Hernandez, Helen W., et al.
Publicado: (2018)